Search PubMed⌕ Search

Biomedical subjects

C Burg

Publications and source records attributed to C Burg.

At least 19 recordsLinked to original sources

Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas.

Recent results have shown the importance of heat-shock proteins (hsp) in immune reactions. In addition, immunization against hsp purified from some immunogenic tumors specifically protects animals from a challenge with the tumor from which the hsp were purified. The protection is dependent on the association between hsp and immunogenic peptides. Using a model of rat colon carcinoma, we studied the importance of hsp70 expression in determining the tumorigenicity of cancer cells in immunocompetent syngeneic animals. Various clones with distinct tumorigenic potentials have been derived from the same parental tumor. Some clones are tumorigenic and others are rejected through an immune-based mechanism. It was observed that among all parameters tested, immunogenicity of tumors co-segregated with expression of inducible hsp70 but not with constitutive hsc70. Variants were obtained from a highly tumorigenic clone (PROb) and from a regressive clone (REGb). The PROb variant (Ph8), selected by repeated sublethal heat shocks, showed an increased capacity for hsp70 synthesis concomitant with a decreased tumorigenicity. Inversely, the REGb variant (REGR73), selected after in vivo growth in partially immunosuppressed rats, acquired tumorigenicity and lost the ability to synthesize hsp70. Expression of other immunologic mediators such as intercellular adhesion molecule-1, MHC I, and MHC II did not co-segregate with tumor immunogenicity. Depletion experiments showed that the immunity elicited by these tumors involves TCR-alpha beta-bearing T cells. Such observations imply that, in this experimental model, inducible but not constitutive hsp70 is involved in immunogenicity of tumors.

Adenocarcinoma↗

Leukaemia Inhibitory Factor derived from rat colon carcinoma cells increases host susceptibility to tumour growth.

We have tested Leukaemia Inhibitory Factor (LIF) production by 12 rat colon tumour clones isolated from a single cell line that display various degrees of tumorigenicity. A highly significantly relationship was found between levels of soluble LIF produced by the clones and their in vivo tumorigenicity. Such results suggested a role for LIF as a tumour facilitating agent. To test this hypothesis, the highly tumorigenic and LIF producing PROb clone was transfected with the LIF cDNA in antisense orientation in order to decrease LIF production. Conversely, REGb, a low LIF producer that is rejected by syngeneic animals, as well as nude mice, was transfected with the LIF cDNA to increase its production. PROb cells transfected with antisense cDNA were shown to have decreased LIF production along with decreased tumorigenicity. LIF-transfected REGb cells expressing high LIF levels still regressed in syngeneic rats, but could form progressive tumours in nude mice. We did not detect LIF receptors on PROb or REGb cells and their in vitro proliferation was not modified by the addition of exogenous LIF. Therefore, LIF was not an autocrine growth regulator for PROb and REGb cells. Instead, LIF appears to facilitate in vivo tumour growth, without being an immunosuppressive factor sufficient on its own to allow growth of immunogenic cells in fully immunocompetent hosts.

Adenocarcinoma↗

An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis.

BACKGROUND/AIMS: Immunotherapy using interleukin 2 has had disappointing results in the treatment of colon cancer. Overcoming escape mechanisms, such as lack of antigen presentation and absence of accessory adhesion molecules on cancer cells, may increase its efficiency. We tried to do so by modifying the phenotype of the weakly immunogenic rat colon cancer PROb cells with sodium butyrate. METHODS: After in vitro treatment with butyrate, PROb cells were tested for lymphokine-activated killer cell sensitivity and, using cytofluorometry, expression of adhesion molecules. We then treated established PROb peritoneal carcinomatoses with intraperitoneal injections of interleukin 2 and butyrate. Tumors were studied histologically and immunohistochemically. We tested the specificity of the immune protection by subsequent subcutaneous challenges with either PROb or glioma cells and by Winn's assay. RESULTS: Butyrate increased lymphokine-activated killer cell sensitivity and expression of major histocompatibility complex class I and intercellular adhesion molecule 1 in vitro. Interleukin 2/butyrate combination resulted in cases of complete cure of carcinomatosis with specific protection against PROb cells. We noticed a complex stroma reaction with numerous functional antigen presenting cells close to PROb cells. CONCLUSIONS: The complete regression of tumor masses may be attributed, at least in part, to a butyrate-induced increase in immunogenicity of the cancer cells. This new combined immunotherapy may be of interest in the treatment of colon cancer.

Adenocarcinoma↗

[Treatment with butyrate/IL-2 combination in peritoneal carcinomatosis of colonic origin].

Two therapeutic assays associating sodium butyrate (NaB) and interleukin-2 (IL-2) were applied on rats after intraperitoneal (i.p.) injection of colon carcinoma cells. The first assay began at day 1 after cell injection, and the second one at day 10 after injection, i.e. when carcinomatosis was established. IL-2 was given i.p. three times per day and NaB one time per day, for five and seven days respectively. The survival median of IL-2 treated rats significantly increased versus those of untreated ones, and was much higher with NaB in supplement. Moreover, using this associative treatment, we observed some cases of complete curacy, even in rats bearing established carcinomatosis.

Animals↗

Failure of monoclonal antibodies against tumor associated antigens to improve tumor targeting of LAK cells in a model of rat colon carcinoma.

The possibility of targeting LAK cells to the tumor by arming them with monoclonal antibodies directed against tumor associated antigens was tested in a rat model of colon carcinoma. Peritoneal carcinomatosis was generated by injection of cloned tumor cells and 111In-labeled LAK cells were injected in the tail vein after preincubation with the monoclonal antibodies themselves. It appeared that the antibodies did not significantly improve tumor targeting of LAK cells, most of the radioactivity being recovered in the spleen, the liver, the kidney or the lung, and only a small fraction in the tumor.

Animals↗

Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity.

The susceptibility to natural-killer-cell lysis and expression of histo-blood-group antigens of 2 clones from a rat colon adenocarcinoma, of variants derived from them and of 17 human colon carcinoma cell lines were assessed in an attempt to determine if the major glycosidic tissue antigens of epithelial cells could influence the NK susceptibility of tumor target cells of epithelial origin. The rat REGb clone, which is relatively NK-sensitive, expressed higher levels of precursor structures T and Tn and lower levels of H antigenic determinants than the PROb clone, which displays higher resistance to NK-cell lysis. Cell variants were obtained from these 2 clones; it appeared that whether the cell variants were selected on the basis of expression of a blood-group antigenic determinant or on the basis of altered susceptibility to NK-cell lysis, there was a link between increased resistance and higher expression of cell-surface A and H histo-blood-group antigens, or conversely, between increased sensitivity and higher expression of precursor structures. Similar conclusions were obtained upon study of the human cell lines, since a significant correlation was found between the level of expression of T or Tn antigens and sensitivity to NK-cell lysis. A significant relationship was found between the expression of Lewis antigens and increased resistance to NK-cell-mediated cytotoxicity.

ABO Blood-Group System↗

Relationship between sensitivity to natural killer cells and MHC class-I antigen expression in colon carcinoma cell lines.

The sensitivity of colorectal tumors to NK-cell-mediated cytotoxicity and their expression of major histocompatibility complex (MHC) class-I antigens were studied in an attempt to determine whether such antigens play a role in the susceptibility of colorectal tumors to NK-cell lysis. In a rat colon-carcinoma model, 2 clones differing in their sensitivity to NK-cell-mediated cytotoxicity were tested for class-I expression; it was seen that the more sensitive cells (REGb) expressed less class-I products than did the resistant cells (PROb). However, when MHC class-I antigen expression was increased by IFN-gamma treatment, no change in NK-cell lysis was found with the PROb cells, while an increase in cytotoxicity was obtained with the REGb cells. After in vivo or in vitro selection of NK-resistant REGb cells, we observed in the selected cells an important decrease in RT-I class-I antigen expression. Fifteen different human colorectal cell lines were also studied for HLA class-I expression and NK-cell susceptibility, and no quantitative correlation between these 2 features was seen. However, cell lines which were deficient in HLA class-I antigens were more sensitive than class-I-positive cells.

Animals↗

Identification and characterization of a rat protein (p 105) auto-antigenic in rats bearing a progressive syngeneic colon carcinoma.

Sera from BDIX rats inoculated with 2 tumor clones derived from a single syngeneic colon carcinoma were assayed by Western blotting for the presence of antibodies against the grafted tumor. The PROb clone is progressive and produces metastases. We observed that rats bearing this tumor developed antibodies against an unglycosylated water-soluble protein of 105 kDa. The magnitude of this humoral response, as assessed by the intensity of the signal on immunoblots, was inversely correlated with survival of the rats. Furthermore, rats inoculated with the REGb clone, which is immunologically rejected, never developed detectable antibodies against the tumor. Antisera from rats injected with PROb tumor detected p105 antigen in cellular extracts from the REGb clone and from a series of rat and human cell lines. This protein was also detected in variable amounts in some normal adult and fetal tissues. Treatment of PROb or REGb cells by either interferon-gamma or heat shock did not significantly alter the expression of the p105 auto-antigen.

Adenocarcinoma↗

[Characterization of autoantigen (p105) in a model of colonic adenocarcinoma in the rat].

Sera from BDIX rats bearing the syngeneic colon tumors PROb or REGb were analysed by Western blotting in order to detect a possible humoral response against the grafted tumor. The PROb clone grows progressively in syngeneic hosts and metastasizes, whereas the REGb clone grows slowly and then is rejected. This model was developed by F Martin and his group in Dijon, France. We observed that rats bearing PROb tumors only develop an antibody response against a water-soluble protein of 105 kDa (p105) which is expressed by both tumor clones. This antibody response has never been detected in rats bearing REGb tumors. The antigen p105 was also expressed by normal adult colon as well as some other foetal or adult tissues. It is also present in extracts from several tumor cell lines including human colorectal carcinoma cell lines. Moreover, the titer of detected antibody at day 30 was inversely correlated with the survival of rats after tumor inoculation, suggesting a possible facilitating role of this antibody response.

Adenocarcinoma↗

Pharmacokinetic studies of mouse monoclonal antibodies to a rat colon carcinoma: I. Comparison of biodistribution in normal rats, syngeneic tumor-bearing rats, or tumor-bearing nude mice.

The pharmacokinetics of two iodine-131-(131I) labeled murine anti-rat colon carcinoma monoclonal antibodies (D3 and E4) were compared in normal Sprague Dawley rats, syngeneic BDIX rats, or nude mice bearing that tumor. Results of antibody uptake after i.v. administration were analyzed in terms of accumulation and localization indices for normal tissues and tumor. Statistically significant differences between rat and mouse tissue biodistribution were found. D3, which reacts in vitro with the tumor and several normal rat tissues, cleared quickly from the blood of rats and was specifically targeted to several normal tissues, notably the lung. Virtually no targeting to the tumor was observed. Nude mice, however, showed a slower blood clearance and specific antibody targeting only in the tumor. Similar results were seen after injection of another antibody, E4, which is tumor-specific in vitro. Data suggest that studies on the xenogeneic nude mouse model may not necessarily be relevant to the choice of monoclonal antibodies for clinical diagnostic imaging or therapy.

Adenocarcinoma↗

Monoclonal antibodies to a rat colon carcinoma: model for monoclonal antibody therapy of solid tumors.

Tumor progression, lung metastasis, and death occur in tumor-bearing BD IX syngeneic rats in a fashion similar to the course of patients with metastatic colon cancer. In an effort to establish a relevant model for monoclonal antibody (MoAb) therapy of tumors, we generated murine MoAb against DHD/TR, a dimethylhydrazine-induced rat colon carcinoma which has been adapted to cell culture. Murine MoAb 17B10 E4 (E4) reacts with the TR tumor and shows weak immunoperoxidase reactivity with normal rat tissues. Murine MoAb 5F7 D3 (D3) reacts with the tumor and a variety of normal rat epithelia. Both are IgG2a and mediate cytotoxicity by rat peripheral blood mononuclear cells. 18D5 F6 (F6) also reacts with the tumor and normal tissues but is an IgG2b and does not mediate cytotoxicity in the presence of rat effector cells. Iodinated E4 and D3 antibodies retained their immunoreactivity. E4 revealed 9.8 x 10(5) antigenic sites per TR cell, with an affinity constant of 9.35 x 10(7) M-1, while D3 demonstrated 2.5 x 10(6) antigenic sites and an affinity constant of 4.2 x 10(7) M-1. Immunoblotting showed that the antigens recognized by D3 and E4 are glycoproteins with molecular weights of 27,000 and 66,000, respectively. F6 failed to react with its antigen present in the blot. This rat colon carcinoma and the monoclonal antibodies described here may provide experimental data useful for implementing monoclonal antibodies in cancer therapy.

Animals↗

Cerebrospinal fluid neuron-specific enolase is reduced in Alzheimer's disease.

Neuron-specific enolase (NSE), a glycolytic enzyme enolase found in brain, was examined in the cerebrospinal fluid and serum of 30 patients with presumptive Alzheimer's disease (AD) and of 13 healthy controls and evaluated as a measure of neuronal functional activity associated with AD. The cerebrospinal fluid NSE levels of patients with AD were significantly reduced and serum NSE levels were significantly increased from controls. Cerebrospinal fluid NSE levels may be representative of central nervous system cell loss or a decrease in neuronal functional activity associated with AD.

Aged↗

Newborn minor physical anomalies and problem behavior at age three.

The authors followed up 136 three-year-olds who had high or low scores for minor physical anomalies of face, head, hands, and feet at birth. Interviews with parents revealed that high-anomaly infants were somewhat more likely to have problem behaviors at age three; this was particularly true for hyperactive-impulsive behavior for boys. Preschool teachers' ratings of hyperactivity, however, did not show a significant relationship to anomaly score. The results suggest some congenital contributors to behavior disorders of childhood, but the relationship between anomalies and problem behavior is weak and limits clinical usefulness of this measure when used alone for identifying a high-risk population.

Child Behavior Disorders↗

Newborn minor physical anomalies and prediction of infant behavior.

The relationship between a newborn score of minor physical anomalies (MPAs) and behavior at ages 1 and 2 was examined. From an initial screening population of 933, 63 high anomaly and 78 low anomaly infants were followed until age 2 by examiners blind for the newborn anomaly score. High anomaly infants were more likely to be temperamentally difficult as rated by parent interview and direct observation. A subgroup of six infants who were considered irritable at both ages 1 and 2 were all from the high anomaly group. However, there was little agreement between behavioral ratings across situations and over time, and there were no significant predictors of behavior problems at age 2 based on any newborn or 1-year measure. These results indicate that the newborn anomaly score by itself is unlikely to prove clinically useful in predicting preschool behavior problems for an unselected population. The usefulness of this measure for other, "high-risk," populations remains to be explored.

Child Behavior↗

Stability and comparability of intellectual measures for cerebral-palsied preschoolers.

Intelligence test scores on the Stanford-Binet Intelligence Scale and the Merrill Palmer Scale were studied for 23 cerebral-palsied children to determine the stability and comparability of these measures during the preschool years as well as the relationship of pyschological gains or losses to clinical diagnoses of the children. Test and posttest data were analyzed for subjects who had participated for one year in a special preschool program for children with neuromotor problems. A high correlation was found between the two intelligence tests both on pretesting (r = .89) and posttesting (r = .83). No significant differences were observed between IQs attained at the three-year level and IQs attained at the four-year level. No associative pattern between etiology of the disability, neuromotor involvement, and intelligence test patterns was determined.

Cerebral Palsy↗